Network meta-analysis

Gallbladder and biliary disease

Type 2 diabetes (adults)

longest follow-upRecorded harmsEach dose separatelyHazard ratio (from event counts)Separate part 2 of a disconnected network

Randomized trials

Treatments

2,485

Participants

Events

In plain language

Across 8 trials with 2,485 participants, 0 of 19 treatments had a clearly better result than placebo on gallbladder and biliary disease, and for 19 the evidence could not tell them apart from placebo. The most favorable estimate was for Semaglutide 14 mg oral once daily (original tablet): hazard ratio (from event counts) 0.14 (95% credible interval 0.00 to 3.44).

Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.

Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Effects compared with Placebo

Hazard ratio (from event counts). Lower values favor the treatment.

Versus Placebo, log scale. Blue: Bayesian random effects posterior median with 95% credible interval (thick) and 95% prediction interval (dashed). Amber diamond: frequentist estimate with 95% confidence interval. Hover over or tab to a row for its values.

Effects of each treatment versus Placebo
Treatment	Bayesian HR (95% CrI)	95% prediction interval	Verdict
Semaglutide 14 mg oral once daily (original tablet) SEMA_PO_14MG_QD	0.14 (0.00 to 3.44)	0.00 to 3.99	Unclear
Sitagliptin SITAGLIPTIN	0.20 (0.00 to 4.75)	0.00 to 6.13	Unclear
Danuglipron 120 mg oral twice daily DANU_PO_120MG_BID	0.50 (0.01 to 23.89)	0.01 to 25.84	Unclear
Danuglipron 10 mg tablet twice daily DANU_PO_10MG_BID	0.51 (0.01 to 28.30)	0.00 to 31.74	Unclear
Danuglipron 40 mg oral twice daily DANU_PO_40MG_BID	0.52 (0.01 to 23.54)	0.00 to 27.79	Unclear
Danuglipron 2.5 mg tablet twice daily DANU_PO_2p5MG_BID	0.53 (0.01 to 26.47)	0.00 to 31.63	Unclear
Orforglipron 24 mg oral once daily ORFO_PO_24MG_QD	0.65 (0.01 to 51.05)	0.01 to 57.43	Unclear
Orforglipron 12 mg oral once daily ORFO_PO_12MG_QD	0.65 (0.01 to 53.48)	0.01 to 59.01	Unclear
Orforglipron 45 mg oral once daily ORFO_PO_45MG_QD	0.66 (0.01 to 51.93)	0.01 to 62.67	Unclear
Semaglutide 7 mg oral once daily (original tablet) SEMA_PO_7MG_QD	0.71 (0.04 to 14.75)	0.03 to 17.59	Unclear
Insulin glargine INS_GLARGINE	0.80 (0.06 to 10.38)	0.04 to 12.64	Unclear
Dulaglutide 0.75 mg subcutaneous once weekly DULA_SC_0p75MG_QW	1.14 (0.05 to 19.65)	0.04 to 23.72	Unclear
Semaglutide 8 mg injection once weekly SEMA_SC_8MG_QW	1.19 (0.07 to 15.37)	0.06 to 19.20	Unclear
Semaglutide 3 mg oral once daily (original tablet) SEMA_PO_3MG_QD	1.58 (0.10 to 27.92)	0.08 to 35.57	Unclear
Semaglutide 2.0 mg subcutaneous once weekly SEMA_SC_2p0MG_QW	2.33 (0.29 to 19.86)	0.21 to 26.72	Unclear
Semaglutide 0.5 mg subcutaneous once weekly SEMA_SC_0p5MG_QW	2.96 (0.36 to 28.50)	0.27 to 38.50	Unclear
Semaglutide 1.0 mg subcutaneous once weekly SEMA_SC_1p0MG_QW	3.13 (0.37 to 32.12)	0.28 to 44.19	Unclear
Semaglutide 16 mg injection once weekly SEMA_SC_16MG_QW	4.07 (0.47 to 43.82)	0.36 to 55.73	Unclear
Danuglipron 80 mg oral twice daily DANU_PO_80MG_BID	8.05 (0.26 to 260)	0.22 to 310	Unclear

Ranking

How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.

League table

Every treatment against every other: hazard ratio (from event counts) of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.

Every treatment in a row compared with every treatment in a column
Row versus column	PLACEBO	SEMA_PO_14MG_QD	SITAGLIPTIN	DANU_PO_120MG_BID	DANU_PO_10MG_BID	DANU_PO_40MG_BID	DANU_PO_2p5MG_BID	ORFO_PO_24MG_QD	ORFO_PO_12MG_QD	ORFO_PO_45MG_QD	SEMA_PO_7MG_QD	INS_GLARGINE	DULA_SC_0p75MG_QW	SEMA_SC_8MG_QW	SEMA_PO_3MG_QD	SEMA_SC_2p0MG_QW	SEMA_SC_0p5MG_QW	SEMA_SC_1p0MG_QW	SEMA_SC_16MG_QW	DANU_PO_80MG_BID
PLACEBO	PLACEBO	7.20 0.29 to 343	5.07 0.21 to 283	1.99 0.04 to 169	1.97 0.04 to 183	1.94 0.04 to 175	1.90 0.04 to 188	1.54 0.02 to 163	1.54 0.02 to 145	1.51 0.02 to 157	1.41 0.07 to 28.31	1.25 0.10 to 17.06	0.88 0.05 to 19.51	0.84 0.07 to 14.53	0.63 0.04 to 10.39	0.43 0.05 to 3.51	0.34 0.04 to 2.75	0.32 0.03 to 2.68	0.25 0.02 to 2.12	0.12 0.00 to 3.80
SEMA_PO_14MG_QD	0.14 0.00 to 3.44	SEMA_PO_14MG_QD	0.71 0.00 to 103	0.26 0.00 to 65.90	0.26 0.00 to 75.87	0.26 0.00 to 74.49	0.26 0.00 to 74.09	0.20 0.00 to 60.07	0.20 0.00 to 57.48	0.20 0.00 to 60.99	0.20 0.00 to 6.82	0.17 0.00 to 11.95	0.13 0.00 to 4.75	0.12 0.00 to 8.45	0.09 0.00 to 2.21	0.06 0.00 to 3.11	0.04 0.00 to 2.08	0.04 0.00 to 2.13	0.03 0.00 to 1.71	0.02 0.00 to 1.85
SITAGLIPTIN	0.20 0.00 to 4.75	1.41 0.01 to 209	SITAGLIPTIN	0.38 0.00 to 99.56	0.36 0.00 to 113	0.37 0.00 to 90.18	0.38 0.00 to 102	0.29 0.00 to 94.25	0.28 0.00 to 84.38	0.28 0.00 to 93.32	0.26 0.00 to 22.65	0.24 0.00 to 17.37	0.17 0.00 to 14.72	0.16 0.00 to 13.71	0.12 0.00 to 8.77	0.08 0.00 to 3.98	0.07 0.00 to 1.48	0.06 0.00 to 1.45	0.05 0.00 to 2.27	0.02 0.00 to 2.68
DANU_PO_120MG_BID	0.50 0.01 to 23.89	3.80 0.02 to 894	2.64 0.01 to 630	DANU_PO_120MG_BID	0.97 0.00 to 358	0.98 0.00 to 313	0.98 0.00 to 354	0.78 0.00 to 353	0.76 0.00 to 291	0.77 0.00 to 349	0.69 0.00 to 83.72	0.63 0.00 to 65.50	0.45 0.00 to 55.28	0.42 0.00 to 49.67	0.31 0.00 to 38.92	0.21 0.00 to 16.24	0.17 0.00 to 12.43	0.15 0.00 to 12.88	0.12 0.00 to 9.33	0.07 0.00 to 5.79
DANU_PO_10MG_BID	0.51 0.01 to 28.30	3.82 0.01 to 1144	2.74 0.01 to 674	1.03 0.00 to 367	DANU_PO_10MG_BID	1.00 0.00 to 352	0.96 0.00 to 435	0.81 0.00 to 387	0.75 0.00 to 369	0.76 0.00 to 391	0.68 0.00 to 114	0.63 0.00 to 80.08	0.44 0.00 to 69.07	0.43 0.00 to 64.72	0.30 0.00 to 45.64	0.22 0.00 to 21.52	0.17 0.00 to 15.98	0.16 0.00 to 14.83	0.12 0.00 to 11.08	0.07 0.00 to 7.07
DANU_PO_40MG_BID	0.52 0.01 to 23.54	3.90 0.01 to 997	2.67 0.01 to 717	1.02 0.00 to 360	1.00 0.00 to 366	DANU_PO_40MG_BID	0.97 0.00 to 355	0.77 0.00 to 350	0.78 0.00 to 314	0.79 0.00 to 300	0.68 0.00 to 97.11	0.64 0.00 to 78.64	0.44 0.00 to 62.75	0.43 0.00 to 49.60	0.31 0.00 to 41.72	0.22 0.00 to 18.90	0.17 0.00 to 14.46	0.16 0.00 to 14.55	0.12 0.00 to 9.77	0.07 0.00 to 6.51
DANU_PO_2p5MG_BID	0.53 0.01 to 26.47	3.84 0.01 to 1023	2.67 0.01 to 760	1.02 0.00 to 404	1.05 0.00 to 404	1.03 0.00 to 333	DANU_PO_2p5MG_BID	0.77 0.00 to 362	0.75 0.00 to 379	0.78 0.00 to 342	0.67 0.00 to 110	0.64 0.00 to 77.96	0.44 0.00 to 62.00	0.45 0.00 to 55.48	0.32 0.00 to 44.51	0.22 0.00 to 18.70	0.17 0.00 to 14.82	0.15 0.00 to 14.05	0.13 0.00 to 11.06	0.06 0.00 to 6.41
ORFO_PO_24MG_QD	0.65 0.01 to 51.05	5.01 0.02 to 1458	3.51 0.01 to 1294	1.29 0.00 to 685	1.24 0.00 to 719	1.31 0.00 to 688	1.29 0.00 to 720	ORFO_PO_24MG_QD	0.99 0.00 to 476	0.96 0.00 to 632	0.90 0.00 to 189	0.82 0.00 to 130	0.56 0.00 to 128	0.55 0.00 to 106	0.42 0.00 to 72.06	0.28 0.00 to 35.89	0.21 0.00 to 26.74	0.20 0.00 to 25.66	0.15 0.00 to 22.51	0.08 0.00 to 19.25
ORFO_PO_12MG_QD	0.65 0.01 to 53.48	5.03 0.02 to 1845	3.55 0.01 to 1438	1.32 0.00 to 685	1.34 0.00 to 896	1.28 0.00 to 810	1.33 0.00 to 798	1.01 0.00 to 602	ORFO_PO_12MG_QD	1.05 0.00 to 499	0.93 0.00 to 204	0.83 0.00 to 165	0.60 0.00 to 129	0.57 0.00 to 125	0.41 0.00 to 81.11	0.29 0.00 to 39.50	0.22 0.00 to 29.57	0.21 0.00 to 28.77	0.16 0.00 to 23.04	0.08 0.00 to 23.72
ORFO_PO_45MG_QD	0.66 0.01 to 51.93	4.99 0.02 to 1512	3.58 0.01 to 1113	1.31 0.00 to 742	1.32 0.00 to 725	1.27 0.00 to 652	1.28 0.00 to 773	1.04 0.00 to 478	0.96 0.00 to 498	ORFO_PO_45MG_QD	0.91 0.00 to 160	0.81 0.00 to 134	0.60 0.00 to 108	0.56 0.00 to 91.70	0.42 0.00 to 67.49	0.28 0.00 to 34.45	0.23 0.00 to 26.29	0.21 0.00 to 26.56	0.16 0.00 to 19.22	0.08 0.00 to 20.26
SEMA_PO_7MG_QD	0.71 0.04 to 14.75	5.02 0.15 to 497	3.87 0.04 to 509	1.45 0.01 to 318	1.47 0.01 to 298	1.48 0.01 to 305	1.49 0.01 to 305	1.11 0.01 to 295	1.07 0.00 to 271	1.10 0.01 to 268	SEMA_PO_7MG_QD	0.90 0.02 to 52.73	0.62 0.03 to 16.53	0.60 0.01 to 39.87	0.47 0.02 to 6.29	0.31 0.01 to 12.27	0.24 0.01 to 8.60	0.22 0.01 to 9.41	0.17 0.00 to 7.34	0.09 0.00 to 9.13
INS_GLARGINE	0.80 0.06 to 10.38	6.00 0.08 to 639	4.23 0.06 to 441	1.60 0.02 to 260	1.59 0.01 to 287	1.57 0.01 to 302	1.56 0.01 to 271	1.23 0.01 to 300	1.20 0.01 to 241	1.24 0.01 to 236	1.11 0.02 to 57.82	INS_GLARGINE	0.71 0.02 to 38.30	0.67 0.03 to 18.51	0.50 0.01 to 25.02	0.35 0.05 to 2.17	0.27 0.01 to 7.10	0.25 0.01 to 6.62	0.19 0.01 to 2.90	0.10 0.00 to 7.89
DULA_SC_0p75MG_QW	1.14 0.05 to 19.65	7.87 0.21 to 775	5.97 0.07 to 799	2.22 0.02 to 485	2.29 0.01 to 462	2.29 0.02 to 418	2.26 0.02 to 483	1.78 0.01 to 450	1.68 0.01 to 370	1.66 0.01 to 425	1.60 0.06 to 34.52	1.40 0.03 to 65.84	DULA_SC_0p75MG_QW	0.95 0.02 to 51.77	0.74 0.03 to 9.79	0.50 0.01 to 17.41	0.38 0.01 to 12.57	0.35 0.01 to 12.61	0.28 0.01 to 9.93	0.13 0.00 to 12.07
SEMA_SC_8MG_QW	1.19 0.07 to 15.37	8.64 0.12 to 921	6.21 0.07 to 703	2.39 0.02 to 413	2.31 0.02 to 388	2.32 0.02 to 419	2.24 0.02 to 463	1.81 0.01 to 378	1.76 0.01 to 358	1.77 0.01 to 343	1.67 0.03 to 84.05	1.49 0.05 to 34.84	1.05 0.02 to 55.70	SEMA_SC_8MG_QW	0.76 0.01 to 33.15	0.51 0.03 to 6.86	0.39 0.01 to 10.61	0.37 0.01 to 10.37	0.29 0.02 to 3.22	0.14 0.00 to 10.25
SEMA_PO_3MG_QD	1.58 0.10 to 27.92	10.56 0.45 to 827	8.28 0.11 to 1058	3.27 0.03 to 665	3.33 0.02 to 631	3.25 0.02 to 670	3.17 0.02 to 695	2.38 0.01 to 575	2.45 0.01 to 515	2.38 0.01 to 606	2.11 0.16 to 42.07	1.99 0.04 to 91.21	1.35 0.10 to 31.44	1.31 0.03 to 71.33	SEMA_PO_3MG_QD	0.68 0.02 to 23.86	0.53 0.02 to 17.22	0.50 0.01 to 17.43	0.39 0.01 to 14.33	0.20 0.00 to 17.78
SEMA_SC_2p0MG_QW	2.33 0.29 to 19.86	17.12 0.32 to 1352	12.33 0.25 to 1115	4.74 0.06 to 662	4.65 0.05 to 695	4.63 0.05 to 683	4.50 0.05 to 683	3.56 0.03 to 628	3.51 0.03 to 568	3.52 0.03 to 563	3.25 0.08 to 132	2.83 0.46 to 21.13	1.99 0.06 to 88.15	1.95 0.15 to 37.00	1.47 0.04 to 50.48	SEMA_SC_2p0MG_QW	0.77 0.03 to 15.86	0.72 0.03 to 15.27	0.57 0.06 to 4.42	0.29 0.00 to 15.33
SEMA_SC_0p5MG_QW	2.96 0.36 to 28.50	22.40 0.48 to 2023	14.69 0.67 to 1123	5.84 0.08 to 964	5.89 0.06 to 1003	5.93 0.07 to 932	5.91 0.07 to 819	4.68 0.04 to 832	4.62 0.03 to 734	4.39 0.04 to 879	4.18 0.12 to 174	3.68 0.14 to 118	2.64 0.08 to 110	2.56 0.09 to 99.45	1.87 0.06 to 63.89	1.29 0.06 to 28.97	SEMA_SC_0p5MG_QW	0.94 0.16 to 5.02	0.73 0.03 to 16.26	0.37 0.01 to 21.15
SEMA_SC_1p0MG_QW	3.13 0.37 to 32.12	24.28 0.47 to 2267	15.73 0.69 to 1172	6.55 0.08 to 915	6.40 0.07 to 1081	6.33 0.07 to 945	6.46 0.07 to 936	5.01 0.04 to 851	4.83 0.03 to 775	4.77 0.04 to 945	4.55 0.11 to 192	4.04 0.15 to 126	2.85 0.08 to 118	2.71 0.10 to 111	2.01 0.06 to 69.85	1.38 0.07 to 31.45	1.07 0.20 to 6.10	SEMA_SC_1p0MG_QW	0.77 0.03 to 18.17	0.40 0.01 to 23.59
SEMA_SC_16MG_QW	4.07 0.47 to 43.82	30.84 0.59 to 3062	21.47 0.44 to 1998	8.17 0.11 to 1307	8.26 0.09 to 1328	8.23 0.10 to 1271	7.99 0.09 to 1233	6.54 0.04 to 1082	6.26 0.04 to 1213	6.31 0.05 to 1117	5.85 0.14 to 281	5.15 0.34 to 91.95	3.62 0.10 to 166	3.39 0.31 to 63.33	2.56 0.07 to 102	1.76 0.23 to 16.31	1.37 0.06 to 30.58	1.29 0.06 to 29.25	SEMA_SC_16MG_QW	0.50 0.01 to 31.50
DANU_PO_80MG_BID	8.05 0.26 to 260	58.84 0.54 to 11995	44.16 0.37 to 8646	15.06 0.17 to 3191	15.23 0.14 to 4071	14.57 0.15 to 3581	15.68 0.16 to 3697	12.95 0.05 to 3886	12.30 0.04 to 4199	12.64 0.05 to 3732	11.45 0.11 to 1174	10.38 0.13 to 722	7.46 0.08 to 791	7.05 0.10 to 562	5.11 0.06 to 438	3.45 0.07 to 200	2.67 0.05 to 149	2.53 0.04 to 140	2.00 0.03 to 122	DANU_PO_80MG_BID

Heterogeneity, fit and convergence

Bayesian random effects (primary)

Heterogeneity (tau): 0.342 (95% CrI 0.072 to 1.346), log scale
Residual deviance: 21.1 for 28 data points
DIC: 34.0 (pD 12.9)
Largest R-hat: 1.001
Smallest ESS: bulk 3,212, tail 4,281
Divergent transitions: 0
Convergence: All criteria met
Priors: PR02 N(0, 5^2); PR05 N(0, 2.5^2); PR09 log normal(-2.1, 1.58^2) on tau^2 (Adverse events, pharm vs pharm)

Inconsistency

Do trials comparing two treatments directly agree with the indirect evidence through other treatments?

No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting.

Small study effects

A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.

Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

NoteOutcome assessment, time point: selected time points span 14 to 57 weeks
NoteOutcome assessment, analysis set: mixed: randomized 1, safety 7
NoteOutcome assessment, definition: mixed: Hypoglycemia adverse event of special interest 1, level 3 severe hypoglycemia 1, not stated 4, severe by ADA or plasma glucose below 3.1 mmol/L with symptoms 1, Zero implied by no hypoglycemia of any kind 1
NoteOutcome assessment, adjudicated: mixed: not stated 7, yes 1
NoteOutcome assessment, intercurrent events (discontinuation): mixed: not stated 7, while_on_treatment 1
NoteOutcome assessment, intercurrent events (rescue): mixed: not stated 7, treatment_policy 1
NoteRisk of bias, blinding: mixed: double_blind 4, open_label 3, single_blind 1
NoteRisk of bias, funding: mixed: industry 7, not_reported 1

Comparability items per trial
Trial	time weeks	analysis set	definition	instrument	adjudicated	proportion method	intercurrent events (discontinuation)	intercurrent events (rescue)	blinding	funding	start year	Eligibility
PIONEER 10	57	safety	not stated	not stated	yes	not stated	while_on_treatment	treatment_policy	single_blind	industry	2017	Japanese adults 20 or older; T2D; HbA1c 7.0 to 10.5 percent on one oral glucose lowering drug
NCT05514535	45	safety	level 3 severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	industry	2022	adults with T2D, BMI 25 or more, HbA1c 7 to 10 percent, basal insulin up to 40 U/day plus metformin with or without SGLT2i
NCT03985293	20	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	age 18 to 75; HbA1c 7 to 10.5 percent; BMI 22.5 (Asia) or 24.5 to 45.4; metformin or diet and exercise
NCT05486065	49	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	age 18 to 64; HbA1c 7.0 to 10.5; BMI 27 or more; on metformin
SUSTAIN™ 5	35	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 or older (20 in Japan); HbA1c 7.0 to 10.0 percent; stable basal insulin with or without metformin; eGFR 30 or more
NCT05086445	14	safety	Hypoglycemia adverse event of special interest	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	Japanese; age 20 to 70; BMI 20 to 35; HbA1c 7.0 to 10.0 diet only or 6.5 to 9.0 on one OAM, withdrawn 28 days
SUSTAIN™	35	safety	severe by ADA or plasma glucose below 3.1 mmol/L with symptoms	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	Japanese; age 20 or older; HbA1c 6.5 to 9.5 percent on one OAD or 7.0 to 10.5 percent on diet and exercise
S002946	26	randomized	Zero implied by no hypoglycemia of any kind	not stated	not stated	not stated	not stated	not stated	open_label	not_reported	2020	age over 20; T2D on liraglutide 0.6 or 0.9 mg; no new diabetes drug for 3 months

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.

Trial data entering this analysis
Trial	Arm	Treatment	Week	Data	Events / N	Source
PIONEER 10	A1	SEMA_PO_3MG_QD	57	arm, events	2 / 131	R0018421:Table 2
PIONEER 10	A2	SEMA_PO_7MG_QD	57	arm, events	1 / 132	R0018421:Table 2
PIONEER 10	A3	SEMA_PO_14MG_QD	57	arm, events	0 / 130	R0018421:Table 2
PIONEER 10	A4	DULA_SC_0p75MG_QW	57	arm, events	1 / 65	R0018421:Table 2
NCT05514535	A1	SEMA_SC_2p0MG_QW	45	arm, events	5 / 288	R0015842:Table 2
NCT05514535	A2	INS_GLARGINE	45	arm, events	2 / 285	R0015842:Table 2
NCT03985293	A1	PLACEBO	20	arm, events	0 / 66	R0006095:Results
NCT03985293	A2	DANU_PO_2p5MG_BID	20	arm, events	0 / 68	R0006095:Results
NCT03985293	A3	DANU_PO_10MG_BID	20	arm, events	0 / 68	R0006095:Results
NCT03985293	A4	DANU_PO_40MG_BID	20	arm, events	0 / 71	R0006095:Results
NCT03985293	A5	DANU_PO_80MG_BID	20	arm, events	1 / 67	R0006095:Results
NCT03985293	A6	DANU_PO_120MG_BID	20	arm, events	0 / 72	R0006095:Results
NCT05486065	A1	SEMA_SC_2p0MG_QW	49	arm, events	2 / 61	R0005510:Table 2
NCT05486065	A2	SEMA_SC_8MG_QW	49	arm, events	1 / 62	R0005510:Table 2
NCT05486065	A3	SEMA_SC_16MG_QW	49	arm, events	3 / 62	R0005510:Table 2
NCT05486065	A4	PLACEBO	49	arm, events	0 / 60	R0005510:Table 2
SUSTAIN™ 5	A1	SEMA_SC_0p5MG_QW	35	arm, events	3 / 132	R0012671:Table 2
SUSTAIN™ 5	A2	SEMA_SC_1p0MG_QW	35	arm, events	1 / 132	R0012671:Table 2
SUSTAIN™ 5	A3	PLACEBO	35	arm, events	0 / 133	R0012671:Table 2
NCT05086445	A1	PLACEBO	14	arm, events	0 / 11	R0003844:Table 2
NCT05086445	A2	ORFO_PO_12MG_QD	14	arm, events	0 / 14	R0003844:Table 2
NCT05086445	A3	ORFO_PO_24MG_QD	14	arm, events	0 / 17	R0003844:Table 2
NCT05086445	A4	ORFO_PO_45MG_QD	14	arm, events	0 / 18	R0003844:Table 2
SUSTAIN™	A1	SEMA_SC_0p5MG_QW	35	arm, events	1 / 103	R0014736:Supplement Table S5
SUSTAIN™	A2	SEMA_SC_1p0MG_QW	35	arm, events	3 / 102	R0014736:Supplement Table S5
SUSTAIN™	A3	SITAGLIPTIN	35	arm, events	0 / 103	R0014736:Supplement Table S5
S002946	A1	SEMA_SC_0p5MG_QW	26	arm, events	0 / 16	R0006360:Supplement Table S2
S002946	A2	DULA_SC_0p75MG_QW	26	arm, events	0 / 16	R0006360:Supplement Table S2

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab